Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

730

Employees730

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

730

Employees730

CORT Key Statistics

Market cap

4.47B

Market cap4.47B

Price-Earnings ratio

49.27

Price-Earnings ratio49.27

Dividend yield

—

Dividend yield—

Average volume

2.90M

Average volume2.90M

High today

$42.60

High today$42.60

Low today

$39.98

Low today$39.98

Open price

$40.59

Open price$40.59

Volume

1.94M

Volume1.94M

52 Week high

$114.71

52 Week high$114.71

52 Week low

$28.66

52 Week low$28.66

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $41.98, giving the company a market capitalization of 4.47B. It carries a P/E multiple of 49.27.

During the trading session on 2026-04-02, Corcept Therapeutics(CORT) shares reached a daily high of $42.60 and a low of $39.98. At a current price of $41.98, the stock is +5.0% higher than the low and still -1.4% under the high.

Trading volume for Corcept Therapeutics(CORT) stock has reached 1.94M, versus its average volume of 2.9M.

The stock's 52-week range extends from a low of $28.66 to a high of $114.71.

CORT News

TipRanks 4d

Corcept Therapeutics presents data from Momentum trial at ACC 2026

Corcept Therapeutics (CORT) presented late-breaking data from its Momentum trial examining the prevalence of endogenous hypercortisolism in patients with resist...

Simply Wall St 6d

Is Corcept Therapeutics Pricing Reflect Its Recent Share Rebound And DCF Upside Potential

For investors considering whether Corcept Therapeutics at around US$38.53 is a bargain or a potential risk, this article walks through what the current price mi...

TipRanks 7d

Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research

Wolfe Research analyst Kalpit Patel upgraded Corcept Therapeutics (CORT) to Peer Perform from Underperform with no price target after the company received appro...

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

28.6%

Sell

More CORT News

TipRanks 7d

Corcept Therapeutics price target raised to $110 from $100 at Canaccord

Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $110 from $100 and keeps a Buy rating on the shares. The firm noted the FDA posted on...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Broadcom

Robinhood Markets

Palantir Technologies

Gilead Sciences

Spotify

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.